Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective

• Published in: PharmacoEconomics 2024, Vol.42 (1), p.5-9
• Main Authors: Coughlan, Diarmuid, Arisa, Oluwatomi, Thomson, Katie, Yu, Ge, Pearson, Fiona, Kernohan, Ashleigh, Gonzalez-Moral, Sonia Garcia, Wallace, Sheila, Rice, Stephen
• Format: Article
• Language: English
• Subjects: Algorithms; Breast cancer; Camptothecin; Cancer therapies; Commentary; Committees; Cost-Benefit Analysis; Decision making; Disease; Estimates; Health Administration; Health Economics; Humans; Immunoconjugates; Life expectancy; Medicine; Medicine & Public Health; Metastasis; Pharmacoeconomics and Health Outcomes; Policy research; Public Health; Quality of Life Research; Receptor, ErbB-2; Technology Assessment, Biomedical; Trastuzumab - therapeutic use; Willingness to pay
• ISSN: 1170-7690; 1179-2027
• DOI: 10.1007/s40273-023-01317-z

1.2 Absolute and Proportional Quality-Adjusted Life-Year (QALY) Shortfall The AS assesses the relative value on the basis of the difference in an individual's expected future healthy life-years (i.e., QALYs), with and without a particular condition [6]. 1.4 National Institute for Health and Care Excellence's (NICE'S) Preferred EQ-5D Data Source NICE requires the EQ-5D-3L value set for the reference case analysis [1, 9]. The NICE preferred mapping function was developed by the Decision Support Unit (DSU), which used the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions (EEPRU) dataset [1, 10, 11]. 2 Case Study: Trastuzumab Deruxtecan (T-DXd) Synopsis NICE invited the manufacturer (Daiichi Sankyo UK) of T-DXd (Enhertu®) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer who have received trastuzumab and a taxane, as part of NICE'S Single Technology Appraisal (STA) process.